The latest update is out from Aligos Therapeutics (ALGS).
Aligos Therapeutics, Inc. initiated a stock option exchange program allowing employees and directors to trade in their higher-priced stock options for a smaller number of new options with more favorable exercise prices. Nearly all eligible options were exchanged, with participants receiving new options at a ratio of either 1.4-for-1 or 3.4-for-1, depending on the initial exercise price. The program concluded with the issuance of Replacement Options for a reduced total number of shares, and these come with a one-year vesting period and are subject to the terms of the Company’s 2020 Incentive Award Plan.
For a thorough assessment of ALGS stock, go to TipRanks’ Stock Analysis page.
